ProSense® system recently received FDA marketing authorization for the treatment of low-risk breast cancer Cryoablation for breast cancer is now included in proposed medical society guidelines for the approved patient population CAESAREA, Israel, Feb. 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the ...

Core Insights - IceCure Medical Ltd. will release its financial and operational results for the nine months ended September 30, 2025, on November 19, 2025, before the Nasdaq Stock Market opens [1] - A conference call to discuss these results and other corporate developments is scheduled for the same day at 10:00 a.m. EST [2] Company Overview - IceCure Medical specializes in developing and marketing advanced liquid-nitrogen-based cryoablation therapy systems aimed at destroying both benign and cancerous tumors through freezing [2] - The company's primary focus areas include breast, kidney, bone, and lung cancer, with its flagship ProSense® system marketed globally [2] Upcoming Events - The conference call will be accessible via a live webcast, and a recording will be available afterward on the company's investor relations website [2]

Core Viewpoint - IceCure Medical Ltd. has completed its rights offering, allowing shareholders to purchase up to 10,000,000 units at a subscription price of $1.00 per unit, generating approximately $10 million in gross proceeds [1][5]. Rights Offering Details - The subscription period for the rights offering expired on July 28, 2025, at 5:00 p.m. Eastern Time [1]. - Each holder of ordinary shares received one subscription right for every share owned, allowing them to subscribe for 0.1703 of a unit, which includes one ordinary share and a warrant [2]. - Holders who fully exercised their basic subscription rights could subscribe for additional units that remained unsubscribed [3]. Subscription Results - A total of 10,000,000 units were validly subscribed during the rights offering, with 4,627,771 units expected to be issued under the over-subscription privilege [4]. - The company plans to deliver the ordinary shares and warrants to rights holders on or about July 30, 2025 [4]. Financial Implications - The estimated gross proceeds from the rights offering are approximately $10 million, excluding related expenses [5]. Company Overview - IceCure Medical develops minimally-invasive cryoablation technology for tumor destruction, focusing on breast, kidney, bone, and lung cancers [10].

Core Viewpoint - IceCure Medical Ltd. is conducting a Rights Offering that allows existing shareholders to purchase units at a subscription price of $1.00 per unit, with the subscription period expiring on July 28, 2025 [1][6]. Group 1: Rights Offering Details - The Company distributed non-transferable subscription rights to holders of its ordinary shares as of July 9, 2025, allowing them to purchase up to 10,000,000 units at a price of $1.00 per unit [2]. - Each holder of the Company's ordinary shares will receive one subscription right for every share owned, with each subscription right entitling the holder to purchase 0.1703 of a unit, which includes one ordinary share and a warrant [6]. - The Rights Offering is being managed by Maxim Group LLC, and all inquiries regarding the offering can be directed to them [7]. Group 2: Subscription Process - Rights holders must contact their brokers or nominees to exercise their subscription rights and submit payment by the deadline, which may be set earlier than July 28, 2025 [3]. - The subscription rights will expire if not exercised by the specified deadline, and no fractional subscription rights or units will be issued [6]. Group 3: Company Overview - IceCure Medical develops and markets advanced cryoablation therapy systems for tumor destruction, focusing on breast, kidney, bone, and lung cancers [12]. - The Company's flagship product, the ProSense® system, is marketed globally and offers a minimally invasive alternative to surgical tumor removal [12].

Core Viewpoint - IceCure Medical Ltd. has initiated a rights offering to raise funds through the sale of subscription rights to existing shareholders, aiming to generate up to $10 million in gross proceeds [1][4]. Rights Offering Details - The rights offering allows holders of the Company's ordinary shares as of July 9, 2025, to purchase up to 10,000,000 units at a subscription price of $1.00 per unit [2][4]. - Each ordinary share owned on the record date grants one subscription right, allowing the purchase of 0.1703 of a unit, which includes one ordinary share and a warrant [3][4]. - The subscription rights will expire on July 28, 2025, unless extended by the Company, and no fractional subscription rights or units will be issued [3][5]. Financial Implications - If fully subscribed, the rights offering is expected to yield gross proceeds of $10 million, which will be used to repay a $2 million bridge loan from Epoch Partner Investments Limited and for general corporate purposes [4][10]. - Epoch, the largest shareholder, has committed to fully participate in the rights offering, potentially subscribing for up to $5 million [4]. Management and Regulatory Aspects - Maxim Group LLC has been appointed as the dealer-manager for the rights offering, and the offering is being conducted under a registration statement declared effective by the SEC [6][7]. - The rights offering is made only by means of a prospectus, which will be provided to eligible shareholders [7]. Company Overview - IceCure Medical specializes in minimally invasive cryoablation technology for tumor destruction, focusing on various cancers including breast, kidney, bone, and lung cancer [10].

Core Viewpoint - IceCure Medical Ltd. announced preliminary financial results for the three and six months ended June 30, 2025, highlighting a decrease in product sales compared to the previous year due to shipment delays and fluctuations in customer orders [1][4]. Financial Performance - The company expects product sales of approximately $525,000 for the three months ended June 30, 2025 [2]. - For the six months ended June 30, 2025, product sales were approximately $1.25 million, a decrease from $1.65 million during the same period in 2024 [4]. - The previous year's sales figure excludes $100,000 from an exclusive distribution agreement with Terumo in Japan [4]. Shipment and Order Flow - Order flow was not impacted by the conflict between Israel and Iran, although some non-U.S. customer shipments were temporarily delayed [2]. - More than $200,000 of product sales from delayed shipments are expected to be recognized in July 2025 [2][3]. - The U.S. market was not affected by shipment delays due to sufficient inventory of ProSense® systems and probes [3]. Future Reporting - IceCure plans to report comprehensive financial results for the second quarter and first half of 2025 in August 2025 [5]. - The company does not intend to issue preliminary financial results on a quarterly basis unless warranted [5]. Company Overview - IceCure Medical develops minimally-invasive cryoablation technology for tumor destruction, focusing on breast, kidney, bone, and lung cancer [7]. - The flagship ProSense® system is marketed globally and serves as a safe alternative to surgical tumor removal [7].

Core Viewpoint - IceCure Medical Ltd. has announced a rights offering to raise up to $10 million, allowing existing shareholders to purchase additional units at specified prices, with the aim of repaying a bridge loan and for general corporate purposes [1][2]. Group 1: Rights Offering Details - The rights offering will provide each shareholder with one subscription right for each ordinary share held as of July 9, 2025, allowing them to subscribe for 0.1703 of a unit at a price of $1.00 per unit or a pre-funded warrant at $0.9999 per unit [1][2]. - The subscription rights will expire on July 28, 2025, at 5:00 p.m. Eastern Time, and shareholders must exercise their rights for at least one whole unit to participate [1][6]. - If fully subscribed, the company expects to receive gross proceeds of $10 million, with Epoch Partner Investments Limited committed to participate with up to $5 million [2]. Group 2: Financial Context - The proceeds from the rights offering will be used to repay a $2 million unsecured bridge loan from Epoch, which carries an interest rate of 4.05% and is due after 12 months or upon completion of the rights offering [2]. - Epoch's director is also a member of IceCure's board, indicating a close relationship between the two entities [2]. Group 3: Company Overview - IceCure Medical specializes in minimally invasive cryoablation technology for tumor destruction, focusing on various cancers including breast, kidney, bone, and lung [8]. - The company's flagship product, the ProSense® system, is marketed globally and offers a safe alternative to surgical tumor removal [8].

Core Viewpoint - IceCure Medical Ltd. is set to release its financial and operational results for Q1 2025 on May 28, 2025, before the Nasdaq opens, followed by a conference call to discuss these results and other corporate developments [1]. Group 1: Company Overview - IceCure Medical specializes in minimally-invasive cryoablation technology that targets tumor destruction through freezing, serving as an alternative to surgical tumor removal [2]. - The company focuses on treating various types of cancer, including breast, kidney, bone, and lung cancer, using its ProSense® system, which is marketed globally [2]. Group 2: Upcoming Events - A conference call will take place on May 28, 2025, at 10:00 a.m. EDT, where the company will discuss its financial results and other developments [1]. - The call can be accessed via a U.S. toll-free number and an international number, with a live webcast available online [2].